FARMINGDALE, N.Y., Sept. 2 /PRNewswire-FirstCall/ -- Misonix, Inc. , a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the restructuring and expansion of its sales organization in Europe. Two business units have been created; one for sales and service of the Sonablate(R) 500 High Intensity Focused Ultrasound (“HIFU”) System and the other for sales and service of the SonaStar(R) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutting System and the SonicOne(R) Ultrasonic Wound Cleansing and Debridement System.
Misonix EMEA (Europe, Middle East, Africa) will continue to sell and service the Company’s non-HIFU product platforms through a growing network of specialty distributors and will continue to be managed by Patrick Kyne, who has more than 20 years of experience with sales organizations in Europe, the Middle East, Africa, Asia, and Latin America. The Company has more than 10 specialty distributors trained and operational with plans to rapidly expand the sales organization.
The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
About Misonix:
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
SOURCE Misonix, Inc.
CONTACT: Richard Zaremba, Misonix, +1-631-694-9555, invest@misonix.com; or
Investor Relations, Kevin McGrath, Cameron Associates, Inc.,
+1-212-245-4577, Kevin@cameronassoc.com
Web site: http://www.misonix.com/
